Vadiraj Kurdekar
About Vadiraj Kurdekar
Vadiraj Kurdekar is a Senior Computational Drug Designer at Exscientia in Oxford, England, with extensive experience in medicinal chemistry and computational research. He holds a Ph.D. in Medicinal Chemistry from Birla Institute of Technology and Science, Pilani, and has worked in various research roles across India and the United Kingdom.
Work at Exscientia
Vadiraj Kurdekar has been employed at Exscientia since 2021, serving as a Senior Computational Drug Designer. His role involves utilizing computational techniques to facilitate drug design processes. He is based in Oxford, England, where he has contributed to the company's mission of advancing drug discovery through innovative computational methods.
Previous Experience at Syngene International Limited
Before joining Exscientia, Vadiraj Kurdekar worked at Syngene International Limited as a Senior Research Investigator from 2019 to 2021. During his tenure, he focused on research initiatives that supported drug development and discovery. His experience at Syngene provided him with a strong foundation in the pharmaceutical industry.
Educational Background in Medicinal Chemistry
Vadiraj Kurdekar earned his Doctor of Philosophy (Ph.D.) in Medicinal Chemistry from the Birla Institute of Technology and Science, Pilani, where he studied from 2008 to 2015. His doctoral research contributed to the field of medicinal chemistry, enhancing his expertise in drug design and development.
Research Experience at inStem
At the Institute for Stem Cell Biology and Regenerative Medicine (inStem), Vadiraj Kurdekar held multiple positions. He served as a Research Scientist in Computational Chemistry from 2014 to 2017 and later as a Senior Research Scientist from 2017 to 2018. His work at inStem focused on computational approaches in stem cell research and regenerative medicine.
Postdoctoral Research at Newcastle University
Vadiraj Kurdekar completed a postdoctoral research fellowship at Newcastle University from 2018 to 2019. In this role, he worked as a Postdoctoral Research Associate, contributing to research projects that advanced the understanding of drug interactions and molecular modeling.